drugset
drugset / Trial / NCT04797806

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC

NCT04797806 ↗

Phase 3 Unknown 206 enrolled Tianjin Medical University Cancer Institute and Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Evaluate the efficacy and safety of Anlotinib plus Icotinib as the first-line treatment in patients with sensitive EGFR concomitant mutations advanced non-small cell lung cancer

Timeline

Start
2021-03-12
Primary completion
2022-04-30
Completion
2023-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 12 mg —
Subject Icotinib Small molecule 125 mg —

Indications

non-small cell lung carcinoma